Shufro Rose & Co. LLC Has $30.99 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Shufro Rose & Co. LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,216 shares of the medical research company’s stock after selling 210 shares during the period. Thermo Fisher Scientific accounts for about 2.8% of Shufro Rose & Co. LLC’s investment portfolio, making the stock its 9th biggest holding. Shufro Rose & Co. LLC’s holdings in Thermo Fisher Scientific were worth $30,986,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of TMO. U.S. Capital Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.1% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 8,606 shares of the medical research company’s stock valued at $4,356,000 after buying an additional 175 shares during the period. Valeo Financial Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.7% in the third quarter. Valeo Financial Advisors LLC now owns 3,399 shares of the medical research company’s stock valued at $1,721,000 after buying an additional 214 shares during the period. Manning & Napier Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.9% in the third quarter. Manning & Napier Group LLC now owns 142,994 shares of the medical research company’s stock valued at $72,379,000 after buying an additional 2,655 shares during the period. Linden Thomas Advisory Services LLC grew its stake in shares of Thermo Fisher Scientific by 8.8% in the third quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company’s stock valued at $783,000 after acquiring an additional 125 shares in the last quarter. Finally, Bfsg LLC grew its position in Thermo Fisher Scientific by 3.9% in the 3rd quarter. Bfsg LLC now owns 4,126 shares of the medical research company’s stock valued at $2,088,000 after purchasing an additional 154 shares during the period. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of analyst reports. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday. Raymond James lifted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. HSBC lifted their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Deutsche Bank Aktiengesellschaft boosted their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Five analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $606.76.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last three months. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Up 0.3 %

Thermo Fisher Scientific stock traded up $1.87 on Friday, hitting $573.60. 1,438,184 shares of the stock traded hands, compared to its average volume of 1,317,052. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68. The firm has a market cap of $218.95 billion, a P/E ratio of 36.79, a price-to-earnings-growth ratio of 2.42 and a beta of 0.80. The business’s fifty day simple moving average is $573.60 and its 200 day simple moving average is $530.14. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.